Pharmacokinetics of temocapril and temocaprilat after 14 once daily oral doses of temocapril in hypertensive patients with varying degrees of renal impairment

British Journal of Clinical Pharmacology

Volumn 44, Issue 6, 1997, Pages 531-536

  Puchler K ^a   Eckl, K M ^b   Fritsche, L ^c   Renneisen, K ^a   Neumayer, H H ^c   Sierakowski, B ^a   Lavrijssen, A T J ^d   Thomsen, T ^b   Roots, I ^e  

^a Sankyo Europe GmbH   (Germany)

^b Pharm PlanNet Contract Research GmbH   (Germany)

^c HUMBOLDT UNIVERSITY   (Germany)

^d Department of Cardiology   (Netherlands)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

ACE inhibitor; Pharmacokinetics; Renal failure; Temocapril; Temocaprilat

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; TEMOCAPRIL; TEMOCAPRILAT;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BILE LEVEL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG EXCRETION; FEMALE; HUMAN; HYPERTENSION; KIDNEY FAILURE; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PRIORITY JOURNAL; SIDE EFFECT;

EID: 0030686479     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1997.t01-1-00622.x     Document Type: Article

References (12)

1. Kelly JG, O'Malley K. Clinical pharmacokinetics of the newer ACE inhibitors - a review. Clin Pharmacokinet 1990; 19: 177-196.
2. Leonetti G, Cuspid C. Choosing the right ACE inhibitor - a guide to selection. Drugs 1995; 49: 516-535.
3. Murdoch D, McTavish D. Fosinopril - a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in essential hypertension. Drugs 1992; 43: 123-140.
4. Stein G, Sierakowski B, Grass P, Haufe CC, Jansa U, Weidinger G. Pharmacokinetics of spirapril and spiraprilat in patients with chronic renal failure. Blood Press 1994; 3(Suppl 2): 47-53.
5. Shioya H, Shimojo M, Kawahara Y. Determination of a new angiotensin-converting enzyme inhibitor (CS-622) and its active metabolite in plasma and urine by gas chromatography-mass spectrometry using negative ion chemical ionization. J Chromatogr 1989; 496: 129-135.
6. Oguchi H, Miyasaka M, Koiwai T, et al. Pharmacokinetics of temocapril and enalapril in patients with various degrees of renal insufficiency. Clin Pharmacokin 1993; 24: 421-427.
7. Nakashima M, Yamamoto J, Shibata M, et al. Pharmacokinetics ot temocapril hydrochloride, a novel angiotensin converting enzyme inhibitor, in renal insufficiency. Eur J Clin Pharmacol 1992; 43: 657-659.
8. Suzuki H, Kawaratani T, Shioya H, Uji Y, Saruta T. Study on pharmacokinetics of a new biliary excreted oral angiotensin converting enzyme inhibitor, temocapnl (CS-622) in humans. Biopharm Drug Dispos 1993; 14: 41-50.
9. Singhvi SIM, Duchn KL, Morrison RA, Willard DA, Everett DW, Frantz M. Disposition of fosinopril sodium in healthy subjects. Br J Clin Pharmacol 1988; 25: 9-15.
10. Sica DA, Cutler RE, Parmer RJ, Ford NF. Comparison of the steady-state pharmacokinetics of fosinopril, lisinopril and enalapnl in patients with chronic renal insufficiency. Clin Pharmacokin 1991; 20: 420-427.
11. Ishizuka H, Konno K, Naganuma H, et al. Temocaprilat, a novel angiotensin converting enzyme inhibitor, is excreted into bile via an ATP-dependent active transporter (cMOAT) that is deficient in Eisai hyperbilirubinemic mutant rats (EHBR). J Pharmacol Exp Ther 1997; 280: 1304-1311.
12. Sorooshian M, Eynon CA, Webb DJ, Eastwood JB. Cough associated with ACE inhibitors: increased frequency in renal failure. Eur J Intern Med 1991; 2: 15-17.